Literature DB >> 26055866

Melatonin Treatment in Children with Developmental Disabilities.

A J Schwichtenberg1, Beth A Malow2.   

Abstract

Melatonin is commonly recommended to treat sleep problems in children with developmental disabilities. However, few studies document the efficacy and safety of melatonin in these populations. This article reviews recent studies of melatonin efficacy in developmental disabilities. Overall, short treatment trials were associated with a significant decrease in sleep onset latency time for each of the disorders reviewed, with 1 notable exception-tuberous sclerosis. Reported side effects were uncommon and mild. Across disorders, additional research is needed to draw disability-specific conclusions. However, studies to date provide positive support for future trials that include larger groups of children with specific disabilities/syndromes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angelman syndrome; Autism; Developmental disabilities; Melatonin; Sleep; Smith–Magenis syndrome

Mesh：

Substances：

Year:  2015        PMID： 26055866      PMCID： PMC4461836          DOI： 10.1016/j.jsmc.2015.02.008

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN： 1556-407X


  42 in total

1.  Melatonin: a panacea for desperate parents? (Hype or truth).

Authors:  R Gupta; J Hutchins
Journal:  Arch Dis Child       Date:  2005-09       Impact factor: 3.791

2.  Pro-convulsant effects of oral melatonin in neurologically disabled children.

Authors:  S H Sheldon
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

3.  Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: six "N of 1" trials.

Authors:  P Camfield; K Gordon; J Dooley; C Camfield
Journal:  J Child Neurol       Date:  1996-07       Impact factor: 1.987

4.  Prolonged-release melatonin for children with neurodevelopmental disorders.

Authors:  Hélène De Leersnyder; Nava Zisapel; Moshe Laudon
Journal:  Pediatr Neurol       Date:  2011-07       Impact factor: 3.372

5.  Use of pharmacotherapy for insomnia in child psychiatry practice: A national survey.

Authors:  Judith A Owens; Carol L Rosen; Jodi A Mindell; Hal L Kirchner
Journal:  Sleep Med       Date:  2010-08       Impact factor: 3.492

6.  Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex.

Authors:  Eleanor Hancock; Finbar O'Callaghan; John P Osborne
Journal:  J Child Neurol       Date:  2005-01       Impact factor: 1.987

7.  Evidence of pineal endocrine hypofunction in autistic children.

Authors:  Gaia Kulman; Paolo Lissoni; Franco Rovelli; Maria Grazia Roselli; Fernando Brivio; Pierangelo Sequeri
Journal:  Neuro Endocrinol Lett       Date:  2000       Impact factor: 0.765

8.  The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.

Authors:  Juthamas Wirojanan; Sebastien Jacquemont; Rafael Diaz; Susan Bacalman; Thomas F Anders; Randi J Hagerman; Beth L Goodlin-Jones
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

9.  Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis.

Authors:  Wiebe Braam; Marcel G Smits; Robert Didden; Hubert Korzilius; Ingeborg M Van Geijlswijk; Leopold M G Curfs
Journal:  Dev Med Child Neurol       Date:  2009-05       Impact factor: 5.449

10.  Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.

Authors:  W Braam; R Didden; M Smits; L Curfs
Journal:  J Intellect Disabil Res       Date:  2008-03
View more
  12 in total

Review 1.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

2.  Sleep in Neurodevelopmental Disorders.

Authors:  Anna J Esbensen; Amy J Schwichtenberg
Journal:  Int Rev Res Dev Disabil       Date:  2016

3.  Incontinence in persons with Angelman syndrome.

Authors:  C Wagner; J Niemczyk; M Equit; L Curfs; A von Gontard
Journal:  Eur J Pediatr       Date:  2016-12-20       Impact factor: 3.183

Review 4.  Angelman syndrome and melatonin: What can they teach us about sleep regulation.

Authors:  Daniella Buonfiglio; Daniel L Hummer; Ariel Armstrong; John Christopher Ehlen; Jason P DeBruyne
Journal:  J Pineal Res       Date:  2020-10-11       Impact factor: 13.007

Review 5.  Melatonin as a Potential Agent in the Treatment of Sarcopenia.

Authors:  Ana Coto-Montes; Jose A Boga; Dun X Tan; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2016-10-24       Impact factor: 5.923

6.  Measurement in saliva from neurotypical adults of biomarkers pertinent to autism spectrum disorders.

Authors:  Helen V Ratajczak; Robert B Sothern
Journal:  Future Sci OA       Date:  2015-11-01

Review 7.  Unmet clinical needs and burden in Angelman syndrome: a review of the literature.

Authors:  Anne C Wheeler; Patricia Sacco; Raquel Cabo
Journal:  Orphanet J Rare Dis       Date:  2017-10-16       Impact factor: 4.123

Review 8.  Efficacy and Safety of Melatonin Treatment in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder-A Review of the Literature.

Authors:  Beata Rzepka-Migut; Justyna Paprocka
Journal:  Brain Sci       Date:  2020-04-07

9.  Sleep/Wake Disruption in a Mouse Model of BLOC-1 Deficiency.

Authors:  Frank Y Lee; Huei-Bin Wang; Olivia N Hitchcock; Dawn Hsiao Loh; Daniel S Whittaker; Yoon-Sik Kim; Achilles Aiken; Collette Kokikian; Esteban C Dell'Angelica; Christopher S Colwell; Cristina A Ghiani
Journal:  Front Neurosci       Date:  2018-11-15       Impact factor: 4.677

10.  Melatonin and Angelman Syndrome: Implications and Mathematical Model of Diurnal Secretion.

Authors:  Justyna Paprocka; Marek Kijonka; Piotr Wojcieszek; Marcin Pęcka; Ewa Emich-Widera; Maria Sokół
Journal:  Int J Endocrinol       Date:  2017-12-12       Impact factor: 3.257
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.